

Division of

# Medical Oncology



Chief: Benjamin Ebert, M.D., D.Phil. (2017–present)

The mission of the Department of Medical Oncology, which is an affiliated division of the Department of Medicine (DOM) at Brigham and Women's Hospital (BWH), is to provide outstanding and compassionate clinical care to patients with cancer, to carry out cutting-edge basic and clinical research, and to provide education and training to the next generation of physicians and scientists who are focused on the biology and treatment of cancer.

## Structure

The Division of Medical Oncology provides a structure in which basic scientists, clinical and translational investigators, and clinical oncologists interact, collaborate, and pool their collective expertise to make significant advances in cancer care and research. The cancer care activities of the Dana-Farber Cancer Institute (DFCI) and BWH are further supported and organized by the Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC).

In 2017, Dr. Benjamin Ebert became the chair of the Department of Medical Oncology at DFCI and chief of the Division of Medical Oncology in the BWH DOM.

Drs. Robert Soiffer and Ann Partridge are vice chairs, with a focus on liquid and solid tumors, respectively.

The organizational structure of the department reflects its clinical and scientific goals and facilitates interaction across disciplines. Clinical care is organized around 14 clinical divisions, reflecting the organ system-based multidisciplinary care for cancer patients. Clinical research is largely organized within these clinical divisions, reflecting the expertise and focus of the respective investigators. Basic science is organized around three programs reflecting the biology, model systems, and methodology of the investigators.

Centers, Divisions, and Programs	Centers, Divisions, and Programs
Adult Survivorship Program (Dr. Ann Partridge)	Hospitalist Medicine (Dr. Martha Wadleigh)
Breast Oncology (Dr. Sara Tolaney)	Leukemia (Dr. Daniel DeAngelo)
Cancer Care Equity Program (Dr. Christopher Lathan)	Lowie Center for Thoracic Oncology (Dr. Pasi Jänne)
Cancer Genetics and Prevention (Dr. Judy Garber)	Lymphoma (Dr. Philippe Armand)
Center for Cancer Therapeutic Innovation (Dr. Leena Gandhi)	McGraw/Patterson Center for Population Sciences (Dr. Eliezer Van Allen)
Center for Community-Based Research (Dr. Glorian Sorensen)	Melanoma (Dr. F. Stephen Hodi)
Center for Immuno-Oncology (Dr. F. Stephen Hodi)	Molecular and Cellular Oncology (Dr. James DeCaprio)
Gastrointestinal Oncology (Dr. Brian Wolpin)	Myeloma (Dr. Kenneth Anderson)
Genitourinary Oncology (Dr. Toni Choueiri)	Neuro-Oncology (Dr. Patrick Wen)
Gynecologic Oncology (Dr. Ursula Matulonis)	Sarcoma (Dr. George Demetri)
Head and Neck Oncology (Dr. Robert Haddad)	Stem Cell Transplant and Cellular Therapies (Dr. Catherine Wu)
Hematologic Neoplasia (Dr. Margaret Shipp)	Zakim Center for Integrative Therapies (Dr. Jennifer Ligibel)
Hematology/Oncology Fellowship Program (Dr. Ann LaCasce)	

Additional layers of organization establish links between faculty in different divisions, promoting collaboration and intellectual cross-fertilization between specialties and research disciplines. Research and clinical centers cut across the department, such as the Center for Immuno-Oncology, Cancer Genetics and Prevention, and the Adult Survivorship Program. The vast majority of faculty in the basic science divisions have secondary appointments in clinical divisions reflecting their clinical practice, providing a natural connection between laboratory-based investigators and their clinical colleagues who perform clinical research.

The Division of Medical Oncology currently includes approximately 280 faculty and more than 250 clinical and research trainees. Changes in the division reflect this growth, and also evolving trends in oncology

treatment and research. The careers of faculty members are developed through mentorship, a robust intellectual community, and a commitment to excellence in clinical care and research.

A defining feature of the Department of Medical Oncology is the integration of outstanding basic cancer research and clinical oncology within the same department. Clinicians in the department have deep understanding of the genetics and biology of cancer and engage in clinical research with deep correlative scientific studies. Nearly all basic scientists in the department are clinically trained and are motivated to link the implications of laboratory findings to potential clinical impact, and to take clinical observations as the inspiration for laboratory studies.

## Clinical Activities

Clinical care is organized around 14 centers based on cancer type or organ system, and each division is responsible for the medical care of patients with malignancies that fall under their purview as well as for orchestrating clinical and translational research for their cancer type. Each clinical center is led by a chief who is an internationally recognized leader in their field. These clinical centers include multidisciplinary clinics and active clinical research programs. Clinical care is delivered in a multidisciplinary approach with colleagues from BWH. The clinical program includes over 200 medical oncologists, who collaborate with surgeons, radiation oncologists, radiologists, pathologists, and other medical specialists.

At the Yawkey Center for Cancer Care and satellites, there were approximately 335,000 outpatient visits in FY21, a 9.6% increase from FY20, and 194,000 visits for chemotherapy infusions in FY21. Because outpatient clinical volume has increased in the last several years, clinical operations have been undergoing continuous improvements to accommodate these changes. Clinical operations are led by Dr. Craig Bunnell, chief medical officer, and Dr. Andrew Wagner, medical director for Ambulatory Oncology, and each clinical center has a clinical director who reports to Dr. Wagner.

Prior to the COVID-19 pandemic, medical oncologists rarely used telemedicine to see patients. By necessity and with COVID-related travel and density restrictions, telemedicine has taken on a greater role in medicine overall. At the height of the pandemic, telemedicine technology was used for almost 60% of DFCI office visits. As the pandemic has evolved in our region of the country, the percentage of patients seen by telemedicine has leveled off to approximately one-third of all exam visits.

Outpatient onsite clinical care is primarily delivered at the Yawkey Center in the Longwood Medical Area (293,000 gross square feet of space) and in Chestnut Hill (129,000 square feet of space). Medical oncologists also see patients at the DFCI satellite locations: Dana-Farber at St. Elizabeth's Medical Center (Brighton, MA), DF/BWCC at Milford Regional Medical Center (Milford, MA), DF/BWCC in clinical affiliation with South Shore Hospital (Weymouth, MA), and Dana-Farber/New Hampshire Oncology-Hematology (Londonderry, NH). Patients are also seen at three Dana-Farber Community Cancer Care physician-based practices, located in Lawrence, Methuen, and Weymouth. The newest satellite, DFCI - Merrimack Valley, opened in early 2020 with approximately 30,000 square feet of space, and an additional clinic site is under construction in Foxborough (34,000 square feet of space).

At the Yawkey Center for Cancer Care and satellites, there were approximately 335,000 outpatient visits in FY21, a 9.6% increase from FY20, and 194,000 visits for chemotherapy infusions in FY21.

These sites extend the geographic area in which we can provide care of the highest quality and level of innovation to cancer patients in the region. Concomitant to this growth, strategic changes have been implemented in quality reporting and Epic workflows to deliver consistent care throughout the network, standardizing the approach to cancer treatment through the Clinical Pathways decision-support system. In a system-wide effort to improve healthcare outcomes for all patients and communities served by DFCI, new initiatives have been implemented to reduce disparities in access to care.

Medical oncologists within the division provide inpatient care to cancer patients hospitalized at BWH and the DFCI inpatient hospital, with a combined average census of 168 patients per day for FY21. There are 14 inpatient oncology teams: eight are dedicated to solid tumors and six are dedicated to hematologic malignancies. Of these, several specialized teams focus exclusively on certain diseases or modalities of treatment, which include bone marrow/stem cell transplantation, CAR-T cell and other cellular therapies, acute leukemia, and immunotherapy. The inpatient service provides comprehensive, multidisciplinary, individualized care for cancer patients at all stages of the care continuum. This includes diagnosis, treatment, the ongoing management of complications due to cancer and/or therapy, as well as palliative treatment and end-of-life care.

While clinical centers are organized by disease or organ system to deliver outpatient oncology clinical care and disease-specific clinical research, cross-disciplinary programs unite the best possible teams of clinicians, scientists, and physician-scientists to collaborate across clinical boundaries. These centers and programs provide a structural mechanism to integrate faculty across disease boundaries. Cross-disciplinary clinical care includes Cancer Genetics and Prevention, Inpatient Care, the Adult Survivorship Program, the Zakim Center for Integrative Therapies, the Cancer Care Equity Program, the Immunotoxicity Program, and the Center for Immuno-Oncology (CIO). The Center for Cancer Therapeutic Innovation is the central node for Phase 1 clinical trials across diseases and drug modalities, incorporating the former activities of the Early Drug Development Center and the clinical components of the CIO.

As part of a system-wide effort to combat structural racism and improve healthcare outcomes for all patients and communities served by DFCI, Dr. Christopher Lathan was appointed chief clinical access and equity officer at DFCI in May 2021, charged with implementing new initiatives to reduce disparities in access to care. While Dr. Lathan has

been leading efforts in this area for some time, this initiative provides additional resources and a new infrastructure for implementation. The associated resources will be used to increase efforts at DFCI to serve the full diversity of the community, increase enrollment of patients from underserved populations in clinical studies, and make system-wide changes to combat structural racism. Specifically, this new role will focus on:

- Leading system-wide efforts to combat structural racism and improve the outcomes of healthcare for all patients and community members served.
- Leveraging knowledge of health equity, social justice, and racism to inform all efforts.
- Implementing a robust measurement agenda for both clinical care and community health outcomes.
- Implementing programs designed to decrease differences in access to digital health by race, ethnicity, language, and community of residence.
- Identifying opportunities to advance the scholarship by DFCI faculty members based on the activities included in this role.
- Expanding partnerships and building upon his success at the Whittier Street Health Center.
- Developing and deploying innovative interventions that address common challenges, as identified throughout community health needs assessments and implementation plans, in collaboration with communities, government, and other organizations.

This new role includes Dr. Lathan's leadership of the Cancer Care Equity Program (CCEP), his access work in the DFCI network, his disparities research, and disseminating the range of DFCI's high quality cancer treatments into the community. The CCEP was established to bridge research and outreach efforts addressing cancer disparities at DFCI. Dr. Narjust Duma, a new faculty member in the Lowe Center for Thoracic Oncology, serves as associate director of the CCEP, working alongside Dr. Lathan. The CCEP aims to broaden access to vulnerable patient populations, collaborating with community partners in a quest for equitable care across the spectrum of cancer-related disease. CCEP staffing includes two full-time clinicians, with part-time physician assistants, nurses, research program management, and administrative support. Since its inception, the program has seen 557 patients as new consults and 440 patients in follow-up visits. These patients have a wide range of diagnoses with referrals to disease centers and specialty clinics within DFCI and BWH.



Drs. Christopher Lathan and Huma Rana. Dr. Lathan was appointed the first faculty director of the Cancer Care Equity Program at DFCI in 2010, and was promoted to chief clinical access and equity officer at DFCI in May 2021.

## Recent Clinical Programs and Initiatives

- The “Patient Choice” initiative improves new patient access by providing new patients in-person appointments on the day of their choosing, including the next day if desired. DFCI was the first cancer center in the country to provide this service and the only one that continues to do so.
- An Acute Care Clinic, launched in September 2018, provides urgent care for established DFCI Longwood-based adult patients who would otherwise be directed to an emergency room, resulting in a 20% reduction in overall emergency room visits and an improvement in subsequent admission rates from such visits from 80% to 28%. In close collaboration with the BWH Department of Medicine, a Cancer Diagnostic Service was created to facilitate the rapid evaluation and diagnosis of previously undiagnosed patients suspected of having cancer. Multiple similar care improvement projects are consistently ongoing.
- The Center for Salivary and Rare Head and Neck Cancers, launched in October 2020 with Dr. Glenn Hanna as the director, is devoted to treating patients with rare and sometimes aggressive cancers arising from the head and neck.
- The Amyloidosis Program for the care of patients with amyloidosis, led by Drs. Giada Bianchi (BWH Hematology) and Rodney Falk (BWH Cardiology), is a multidisciplinary BWH/DFCI program which has rapidly expanded over the past decade. The formal program in oncology was first launched in mid-2019 and provides expertise in the diagnosis, treatment, and multidisciplinary care of patients with AL (light chain) amyloidosis and ATTR (transthyretin) amyloidosis associated with MGUS/smoldering myeloma.
- The expansion of the Immune Effector Cell (IEC) Therapy Program: originally developed to provide a comprehensive and systematic multidisciplinary approach for well-regulated, fully supported, and efficiently coordinated clinical trials within Hematologic Malignancies, the IEC clinical and research infrastructure is being extended to support solid tumor trials.
- Implementation of the DF/BWCC Cancer Diagnostic Service for rapid workup and diagnosis for undiagnosed patients suspected of having cancer.

## Research Activities

The Division of Medical Oncology oversees 79 independent laboratories. Basic research is organized around three divisions within the DFCI Department of Medical Oncology, creating communities of investigators with similar interests and approaches: Hematologic Neoplasia focuses predominantly on hematologic malignancies; Molecular and Cellular Oncology focuses predominantly on solid tumor biology; and Population Sciences encompasses epidemiology, outcomes research, and computational biology. Investigators in each division collaborate widely with clinicians and scientists in other divisions within Medical Oncology, other DFCI departments, and external investigators.

Many DFCI investigators have formal appointments at the Broad Institute of MIT and Harvard, and all are active members of the Dana-Farber/Harvard Cancer Center (DF/HCC). Research is undertaken within 163,858 net assignable square feet of research space at DFCI, with several members also working in research space at BWH in the Channing Division of Network Medicine and other sites.

Dana-Farber investigators have helped lead the transformation in new therapies for cancer. The division leads a large number of cross-disciplinary programs that span clinical care and both basic and clinical research, including the Adult Survivorship Program, the Cancer Care Equity Program, Cancer Genetics and Prevention, the Center for Cancer Genomics, the Center for Cancer Therapeutic Innovation, the Center for Community-Based Research, the Center for BRCA and Related Genes (BRCA Center), the Immune-Effector Cell Therapy Program, the Center for Immuno-Oncology, the McGraw/Patterson Center for Population Sciences, and the Robert and Renée Belfer Center for Applied Cancer Science.

In addition, division members play a critical role in the DF/HCC, competitively re-funded as one of the largest comprehensive cancer center grants by the National Institutes of Health (NIH) in 2016, leading several of the programs, cores, and other structures within the center.

## Recent Initiatives

- The BRCA Center launched in 2020 under the leadership of Dr. Panos Konstantinopoulos, director, and co-directors Drs. Judy Garber and Dipanjan Chowdhury. The center is dedicated to the care for, prevention of, and research into BRCA-related cancers.
- The Center for Cancer Genomics (CCG) resulted from a 2020 merger between the Center for Cancer Genome Discovery and the Center for Cancer Precision Medicine. Under the leadership of Drs. Bruce Johnson and Matthew Meyerson, the CCG is the research and development group within the Precision Cancer Medicine effort at DFCI, BWH, and Boston Children's Hospital (BCH). The mission of the center is to facilitate the design, execution, and analysis of cancer research projects through collaborations with investigators. CCG continually develops and adapts new technologies to accelerate discoveries in cancer genomics and applies these discoveries to improve personalized patient care.
- In 2018, the Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF), led by Drs. Jerome Ritz, director, and Sarah Nikiforow, assistant director, expanded to 30,000 square feet, almost triple its former size, to meet the challenges associated with manufacturing therapeutic cells for an increasing number of disease indications. The CMCF provides state-of-the-art stem cell products, as well as cancer vaccines and innovative adoptive T cell and NK cell therapies for DFCI and the larger DF/HCC. In aligned studies, many division members are analyzing the components of an effective or ineffective anti-tumor response and increasing anti-tumor immunity with approaches including reduced intensity allogeneic stem cell transplantation, vaccinations, checkpoint blockade, and engineered T cell and NK cell products.

## Clinical Research: Contributions to DF/HCC

- Faculty members in the division were principal investigators (PIs) on over 1,000 clinical trials from 2016-2019. As of FY19, members of the division led 637 clinical trials, 521 of which were interventional. Among the 142 FDA oncology approvals over the last decade, Dana-Farber investigators played a major role in the development of 32 drugs. Medical oncology faculty led 219 interventional therapeutic trials that first opened in 2019 accruing more than 2,700 patients, and, at any given time in 2019, the division had more than 790 therapeutic trials open. These trials focused on novel therapeutics, early-stage drug development, and the use of biomarkers to assess outcome, and were conducted through DF/HCC.
- Most non-trainee faculty of the division are members of DF/HCC, and a number of the program leaders of DF/HCC are division members, including the program leaders or co-leaders of the following programs: Breast Cancer (Dr. Eric P. Winer); Cancer Cell Biology (Dr. Kornelia Polyak); Cancer Risk, Prevention, and Early Detection Program (Dr. Sapna Syngal); Developmental Therapeutics (Dr. Geoffrey Shapiro); Gastrointestinal Malignancies (Dr. Brian Wolpin); Gynecologic Cancers (Dr. Ursula Matulonis); Kidney Cancer (Dr. Toni Choueiri); Leukemia (Dr. David Weinstock); Lung Cancer (Dr. Bruce Johnson); Lymphoma and Myeloma (Drs. Anthony Letai and Irene Ghobrial); Melanoma (Dr. F. Stephen Hodi); and Prostate Cancer (Dr. Mary-Ellen Taplin).
- In addition, several division members are core leaders in the DF/HCC. The cores of the DF/HCC are available to all DF/HCC members and are designed to provide unique services to basic, clinical, and translational cancer investigators to accelerate their research.

## Clinical Research: Major Accomplishments Over the Last Five Years

- The successful funding and renewal of multiple Specialized Programs of Research Excellence (SPORES) in breast cancer, gastrointestinal cancer, targeted therapies for glioma, kidney cancer, multiple myeloma, myeloid malignancies, and ovarian cancer; and translational program project/center grants in immunogenicity, multiple myeloma, prostate cancer, and lung cancer, among others. Large Stand Up to Cancer (SU2C) grants have been funded for “Identifying and Targeting Mechanisms of Resistance to Immunotherapy” and “Integrating Experimental and Computational Pipelines to Develop Biomarkers of Tumor Cell Resistance to NK Cells.” Recent grants to support sequencing and analysis of human tumor specimens have also been funded.
- Launching the Center for Cancer Therapeutic Innovation, aimed at creating a comprehensive, integrated program of translational early-drug development, including targeted therapies and immunotherapy, led by Dr. Leena Gandhi.
- The development and implementation of a training program for clinical investigators, specifically targeted at the early-career faculty and senior fellows, and improved infrastructure to support clinical trial research. Since implementation in 2014-2015, 85 physicians have completed the “Methods in Clinical Research” course. In the fall 2021 “Methods in Clinical Research” course, 19 physicians enrolled or audited.
- The development and implementation of the Immuno-Oncology Investigator Training Program, which was designed to develop the next generation of leaders in immuno-oncology and to increase the number of investigators with expertise in immuno-oncology, to facilitate research involving immunotherapies. Thirty participants enrolled in the first year of this course. Also, an annual Immune-Related Toxicities Workshop for physicians, nurses, and mid-level providers convenes experts from a variety of internal medicine subspecialties and medical oncologists with deep immunotherapy expertise to present topics related to the mechanisms, clinical manifestations, and management of toxicities resulting from immunotherapy.
- Monthly Medical Oncology Grand Rounds were reintroduced in 2018 to keep all faculty up to date on major discoveries and progress in oncology across the division, with clinical and basic researchers paired for lectures that reflect on research and treatments that span bench to bedside and back. This forum has been put on hold due to the COVID-19 pandemic, and will resume when meetings can be held in person.



Drs. Julia Rotow and Bruce Johnson. Drs. Rotow and Johnson work in the DFCI Lowe Center for Thoracic Oncology. Dr. Johnson also leads the DF/HCC Lung Cancer program.

## Advances in Cancer Medicine

There have been major advances in the care of cancer patients over the last decade, resulting in a significant decline in cancer death rates over the last few years. Members of the division have contributed significantly to these advances through leadership and significant clinical trial activities. Some of these advances include:

- A research portfolio encompassing large and diverse areas of clinical investigation, with a mixture of investigator-initiated and industry-sponsored trials at all phases of development that aim to advance the treatment of cancer at all stages of diagnosis, including recurrence, and seeking to bypass drug resistance.
- Pioneering work understanding genomic heterogeneity and mechanisms of treatment resistance in gastroesophageal cancer. This has been particularly important in HER2-amplified cancers, where multiple new approaches to treating HER2-amplified gastroesophageal cancer are now in clinical trials. (Drs. Adam Bass, Eirini Pectasides, and Nilay Sethi)
- Using paired germline and somatic DNA sequencing in identifying personalized treatment approaches for patients with pancreatic cancer and

determining the inherited pathogenic mutations that predispose to pancreatic cancer. National guidelines have been changed to recommend germline and somatic DNA sequencing for all patients with pancreatic cancer. (Drs. Andrew Aguirre, Matthew Yurgelun, and Brian Wolpin)

- Early involvement and leadership in PARP inhibitor studies, and development of PARP inhibitor and other DNA repair molecule inhibitor combination trials in order to counteract PARP inhibitor resistance. This work has led to FDA approval of PARP inhibitors for use in recurrent ovarian cancer. (Drs. Ursula Matulonis, Joyce Liu, Panos Konstantinopoulos, and others)
- The discovery of PD-L1; multiple clinical studies showing the remarkable potential of anti-PD-1 and anti-PD-L1 antibodies for immunotherapy of patients with cancer; the discovery of new cellular and microenvironmental immunotherapy targets; important advances in the uses of immunotherapeutic drugs, either alone or in combination, and clinical use as approved standard of care treatments. (Drs. Gordon Freeman, F. Stephen Hodi, Philippe Armand, Margaret Shipp, David Reardon, and others)

- The expansion of highly effective combination therapies for myeloma involving thalidomide derivatives and bortezomib, with numerous studies currently testing new generations of proteasome inhibitors, HDAC inhibitors, and immune therapies. (Drs. Kenneth Anderson and Paul Richardson)
- The development and testing of new cancer vaccine strategies, particularly in the areas of antigen presentation and adjuvants. (Drs. Catherine Wu and Patrick Ott)
- Advances in the adjuvant treatment of small, HER2-positive breast cancers with paclitaxel and trastuzumab. (Drs. Sara Toloney and Eric P. Winer)
- Multiple studies on the mechanisms of resistance to ALK and EGFR inhibitors in lung cancer and strategies to avert and bypass resistance mechanisms. (Drs. Pasi Jänne, Bruce Johnson, and others)
- The development of successful new small-molecule drugs for chronic lymphocytic leukemia. (Drs. Jennifer Brown, Matthew Davids, and Catherine Wu)
- The discovery of a new preleukemic disorder, clonal hematopoiesis of indeterminate potential (CHIP), marked by the steady accumulation of mutations characteristic of leukemia in otherwise normal individuals. (Dr. Benjamin Ebert)

## Basic and Translational Research

During the last few years, basic and translational research in the division has expanded considerably through recruitment and implementation of the DFCI strategic plan for research. Total research expenditure for investigators in medical oncology exceeded \$180 million as of FY19. Two members of the division are funded by the Howard Hughes Medical Institute, eight investigators have R35 Outstanding Investigator Awards, nine lead Program Project/SPORE Grants (P01 and P50), 32 faculty provide clinical or basic science leadership on one or more SPORE grants, 12 are PIs on Department of Defense federal grants, and two lead SU2C grants. DFCI investigators lead a wide range of clinical trials. In FY20, members of the Division of Medical Oncology led 663 therapeutic clinical trials.

Although there is a wide variety of research conducted in the division, a particular focus has been on discovering the genetic events that lead to different cancers, and translation to clinic and communities. Division members have contributed to basic research and discovery, clinical development, and recent FDA approval of multiple enzyme and proteasome inhibitors and thalidomide derivatives, and have made significant contributions to understanding mechanisms of action of a broad spectrum of agents, their associated toxicities, and pathways of therapeutic resistance. Some notable investigations and discoveries include:

- Groundbreaking work on oxygen sensing was recognized with the 2019 Nobel Prize in Medicine and led to the development of HIF2 $\alpha$  modulating compounds for cancer treatment. (Dr. William Kaelin)

- The development of a vaccine to target MUC1 expressing malignancies, including hematologic malignancies, such as acute myeloid leukemia (AML) and multiple myeloma. The AML vaccine and another in multiple myeloma are presently under evaluation in multicenter national trials. (Dr. Donald Kufe)
- The discovery that WRN helicase is a synthetic lethal target in microsatellite unstable cancers, which may be exploited for cancer therapeutics. (Drs. Marios Giannakis and Adam Bass)
- The systematic identification of cancer dependencies, using genome-level functional screens in diverse human cancer cell lines to provide a foundation for a cancer-dependency map that facilitates the prioritization of therapeutic targets. (Dr. William Hahn)
- The charting of oncogenic signaling pathways in the Cancer Genome Atlas to reveal a detailed landscape of pathway alterations in 33 cancer types, stratified into 64 subtypes, identifying patterns of co-occurrence and mutual exclusivity, and indicating opportunities for combination therapy. (Drs. Matthew Meyerson, Eliezer Van Allen, and collaborators)
- Discovery of DNA repair gene mutations in ovarian, breast, pancreatic, prostate, and other cancers; basic research into their mechanisms with relationships to other genes and gene defects; and ongoing clinical trials and therapeutic development. (Drs. Geoffrey Shapiro, Ursula Matulonis, Mark Pomerantz, Khanh Do, James Cleary, and others)

- Discovery of mutations in MYD88 as the cause of Waldenström's macroglobulinemia and development of the BTK inhibitor ibrutinib as a highly effective therapy for this disease. (Dr. Steven Treon)
- Studies with genetically engineered mouse models of lung cancer, identifying multiple new therapeutic strategies, including CDK7 inhibitors. (Dr. Pasi Jänne and others)
- Demonstration of extensive reprogramming of the androgen receptor cistrome in prostate cancer. (Dr. Matthew Freedman)

## Educational Activities

Education of students, residents, clinical fellows, and postdoctoral fellows is a central mission of the Department of Medical Oncology. The Dana-Farber Cancer Institute/Mass General Brigham hematology/oncology fellowship program, the largest in the country, provides outstanding clinical training and unparalleled research opportunities. Co-led by Dr. Ann LaCasce, a faculty member in the Department of Medical Oncology, the program enrolls 16 fellows per year. Following the first year of clinical training, fellows can pursue further clinical training at DFCI, Massachusetts General Hospital (MGH), or BWH. In addition, fellows can pursue research throughout the Harvard/MIT community, including DFCI, any of the Harvard institutions, the Broad Institute, the Koch Institute at MIT, or other MIT departments. Many of these outstanding trainees have become long-term faculty members in medical oncology.

Outside DFCI, graduates of the fellowship program have become international leaders in

their fields, cancer center directors, chiefs of hematology/oncology, leaders in biotechnology and pharmaceutical companies, and leaders in federal government health agencies (e.g., National Cancer Institute). Fourteen first-year fellows are selected annually from a pool of more than 450 applicants. During the first year of training, fellows spend six months at DFCI/BWH and six months at MGH. Approximately one-quarter of the fellows elect to receive training in both oncology and hematology, resulting in an additional six months of clinical training, which includes six intensive inpatient weeks on the bone marrow transplant unit at BWH or MGH.

More than 50% of fellows have a Ph.D. as well as an M.D., approximately 50%-70% of fellows enter basic science laboratories, 20% participate in the annual "Clinical Effectiveness" course offered at the Harvard T.H. Chan School of Public Health (HSPH) and subsequently conduct research in epidemiology or health services, and 25% focus their research

The Dana-Farber Cancer Institute/  
Mass General Brigham hematology/  
oncology fellowship program, the  
largest in the country, provides  
outstanding clinical training and  
unparalleled research opportunities.



Drs. Panos Konstantinopoulos and Ursula Matulonis. Dr. Konstantinopoulos serves as director of the BRCA Center. Dr. Matulonis is chief of the Division of Gynecologic Oncology.

efforts on clinical trials. We are pleased to note that more than 85% of the graduates of this program over the last ten years remain in academic positions. The division works closely with the Division of Hematology at BWH, led by Dr. Nancy Berliner.

In addition, the Department of Medical Oncology contributes to education through advanced fellowships in breast oncology, hematologic malignancies/stem cell transplant, and early drug development. Faculty in medical oncology are the attending physicians on oncology and bone marrow transplant services at BWH and therefore have the opportunity to teach medical residents at BWH. The Training in Oncology Population Sciences (TOPS) postdoctoral program, led by Dr. Deborah Schrag, trains postdoctoral fellows in population sciences.

While serving as attending physicians on the oncology inpatient service of BWH, members of the division actively instruct medical residents from BWH in various aspects of oncology. The division provides attending physicians for 11 teams each month. An experience in ambulatory oncology is also available to interested medical residents, who may choose to spend several weeks in one or more disease centers or several afternoons with a given faculty member.

Faculty in medical oncology participate in the education of Harvard Medical School (HMS) students through a variety of programs. A subspecialty

hematology/oncology elective combines two weeks on the BWH inpatient hematology consult service and two weeks in DFCI's outpatient oncology clinics. The Department of Medical Oncology also hosts a stem cell transplantation elective. Dr. Harold Burstein co-directs the "Advanced Integrated Science: Cancer Biology" course for third- and fourth-year students. The Poussaint Pre-matriculation Summer Program is hosted by the department for underrepresented minority students who are about to enter HMS.

Finally, many faculty members teach in Continuing Medical Education (CME) courses, and several courses are organized by medical oncology faculty members. Dr. Robert Mayer leads the "Cancer Medicine and Hematology" course, a four-day overview of hematology and medical oncology, and the DFCI Master Class program, a series of two-day programs given at several sites around the country to update community oncologists on new advances in cancer management.

Many of the disease centers within the division also present annual or semiannual half-day programs for regional physicians and other health professionals, including the Gastrointestinal Cancer Program, the Genitourinary Cancer Program, the Head and Neck Oncology Program, the Hematologic Malignancies Program, and the Women's Cancer Program. Many members of the division participate in weekly tumor boards at several community hospitals throughout eastern New England and in CME courses across the country.

## Challenges and Future Directions

The division's plans for the future include:

- Seamlessly incorporating 21st century technology into clinical trials and healthcare to improve patient outcomes.
- Engaging new clinical and research faculty with complementary areas of expertise.
- Accelerating development of precision medicine, combination therapies, and germline testing of cancer patients.
- Creating cancer care equity by broadening access to care for vulnerable and underserved patient populations across the spectrum of cancer-related disease.
- Developing strategies to precisely target and predict response and resistance to therapies, either singly or in combination, and either rationally or through testing of patient-derived models.
- Preventing cancer by making the new technology that we discover widely available.
- Expanding survivorship services.
- Continuing to improve our faculty model and developing more robust training and support programs for clinical investigators, and expanding clinical activities to a larger network of affiliated centers.
- Developing strategies to predict which patients will respond to various immunotherapies.

Burnout is a difficult challenge for all faculty, and based on internal survey data, is particularly acute for clinical faculty. The Center for Faculty Wellbeing was launched in 2019, with Dr. Jennifer Ligibel as its inaugural director. The center focuses on finding meaningful ways to alleviate stress inherent to the practice of medicine. Wellbeing initiatives have included mental health programs, a sleep health program, and childcare resources – all of which have been particularly important during the COVID-19 pandemic.

The relationship between the Department of Medical Oncology and BWH is critical for DFCl's inpatient and outpatient clinical care. Faculty at DFCl and BWH interact through a vast network of clinical partnerships and research collaborations. We will continue to work within the DF/BWCC framework to plan for adequate clinical and infusion space throughout the distributed

campus. As therapies for common solid tumors have led to substantial increases in lifespan over the last few years, the number of patients remaining under care at DFCl has and will continue to increase steadily. This presents a challenge to us for space planning and makes it essential that we continue to improve the efficiency, safety, and effectiveness of care delivered by medical oncologists.

This also increases the imperative to expand and improve survivorship training and care. The division is committed to expanding its impact on cancer through basic, clinical, and translational research. Our rapidly evolving understanding of the cellular and molecular pathogenesis from precancerous states to full-blown malignancy is rapidly translating into novel, targeted therapies that are remarkably effective.

The opportunities in cancer research in the coming years are tremendously inspiring, with novel therapeutics entering the clinic, powerful tools for interrogating cancer biology, diagnostics for precision medicine, and the potential to develop improved combination therapies. The fundamental strength of the Department of Medical Oncology is the outstanding faculty and the remarkable integration of outstanding basic and translational research with clinical practice within the same department. Our central goal is recruiting and retaining the best possible physicians and scientists, and enabling them to succeed.

Finally, as in all areas of medicine, critical analysis of the effectiveness of current therapies and their impact on quality of life and the economics of healthcare needs to play an increasing role in medical decision-making. The division has new programs and a growing interest in the fields of patient safety, psychosocial oncology, adolescent cancer medicine, population genetics, and health administration.

The major challenges facing the division include the increasing costs of cancer care, resource requirements, and regulatory issues in clinical care and investigation; the difficulty in training, funding, finding protected time for, and retaining talented clinical investigators; the growing knowledge gap between basic cancer investigators and clinical oncologists; and the difficulty in obtaining sufficient financial support for both clinical and basic research in the current economic environment.

The Center for Faculty Wellbeing focuses on finding meaningful ways to alleviate stress inherent to the practice of medicine. Wellbeing initiatives have included mental health programs, a sleep health program, and childcare resources – all of which have been particularly important during the COVID-19 pandemic.

# Faculty Roster

## Professor Emeritus

George Canellos, M.D.

## Professor

Kenneth Anderson, M.D.

Joseph Antin, M.D. Edward

J. Benz, Jr., M.D. Jennifer

Brown, M.D., Ph.D.

Myles Brown, M.D.

Harold Burstein, M.D., Ph.D.

Toni Choueiri, M.D.

Daniel DeAngelo, M.D., Ph.D.

James DeCaprio, M.D.

George Demetri, M.D.

Benjamin Ebert, M.D., D.Phil.

Arnold Freedman, M.D.

Gordon Freeman, Ph.D.

Judy Garber, M.D.

Wendy Garrett, M.D., Ph.D. (Immunology and Infectious Diseases, HSPH)

Irene Ghobrial, M.D.

James Griffin, M.D.

Robert Haddad, M.D.

William Hahn, M.D., Ph.D.

F. Stephen Hodi, M.D.

Pasi Jänne, M.D., Ph.D.

Bruce Johnson, M.D.

William Kaelin, Jr., M.D.

Tari King, M.D. (Surgery)

Donald Kufe, M.D.

Anthony Letai, M.D., Ph.D.

Ursula Matulonis, M.D. Robert

Mayer, M.D. Jeffrey

Meyerhardt, M.D.

Matthew Meyerson, M.D., Ph.D. (Pathology/Medicine)

Elizabeth Mittendorf, M.D., Ph.D. (Surgery)

Nikhil Munshi, M.D.

Ann Partridge, M.D.

Kornelia Polyak, M.D., Ph.D.

David Reardon, M.D.

Timothy Rebbeck, Ph.D. (Epidemiology, HSPH)

Ellis Reinherz, M.D.

Paul Richardson, M.B., B.S.

Jerome Ritz, M.D.

Barrett Rollins, M.D., Ph.D.

Deborah Schrag, M.D.

William Sellers, M.D.

Geoffrey Shapiro, M.D., Ph.D.

Margaret Shipp, M.D.

Ramesh Shivdasani, M.D., Ph.D.

Robert Soiffer, M.D.

Glorian Sorensen, Ph.D. (Social and Behavioral Sciences, HSPH)

Richard Stone, M.D.

Christopher Sweeney, M.B., B.S.

Sapna Syngal, M.D.

Mary-Ellen Taplin, M.D.

Steven Treon, M.D., Ph.D.

Kasisomayajula Viswanath, Ph.D. (Social and Behavioral Sciences, HSPH)

David Weinstock, M.D.

Patrick Wen, M.D. (Neurology)

Eric P. Winer, M.D.

Catherine Wu, M.D.

## Associate Professor

Gregory Abel, M.D.

Philippe Armand, M.D., Ph.D.

David Barbie, M.D.

Adam Bass, M.D.

Himisha Beltran, M.D.

Rameen Beroukhim, M.D., Ph.D.

Jorge Castillo, M.D.

Corey Cutler, M.D.

Matthew Davids, M.D.

Christina Dieli-Conwright, Ph.D.

Peter Enzinger, M.D.

David Frank, M.D., Ph.D.

Matthew Freedman, M.D.

Rachel Freedman, M.D.

Suzanne George, M.D.

Michael Hassett, M.D.

Vincent Ho, M.D.

Joseph Jacobson, M.D.

Panagiotis Konstantinopoulos, M.D., Ph.D.

John Koreth, M.B., B.S., D.Phil.

Ian Krop, M.D., Ph.D.

Ann LaCasce, M.D.

Andrew Lane, M.D., Ph.D.

Eudocia Lee, M.D. (Neurology)

Jennifer Ligibel, M.D.

Nancy Lin, M.D.

Jochen Lorch, M.D.

Kimmie Ng, M.D.

Patrick Ott, M.D., Ph.D.

Beth Overmoyer, M.D.

Rizwan Romee, M.D.

Guru Sonpavde, M.B., B.S.

Sara Tolaney, M.D.

Eliezer Van Allen, M.D.

Andrew Wagner, M.D., Ph.D.

Jia-huai Wang, Ph.D. (Pediatrics, BCH)

Brian Wolpin, M.D.

Alexi Wright, M.D.

# Faculty Roster (continued)

## Assistant Professor

Thomas Abrams, M.D.

Andrew Aguirre, M.D., Ph.D.

Mark Awad, M.D., Ph.D.

Caroline Block, M.D.

Elizabeth Buchbinder, M.D.

Craig Bunnell, M.D.

Susana Campos, M.D.

Jennifer Chan, M.D.

Wendy Chen, M.D.

Atish Choudhury, M.D., Ph.D.

James Cleary, M.D., Ph.D.

Andrea Enzinger, M.D.

David Fisher, M.D.

Jacqueline Garcia, M.D.

Marios Giannakis, M.D., Ph.D.

Mahasweta Gooptu, M.B., B.S.

Alexander Gusev, Ph.D.

Glenn Hanna, M.D.

Rizwan Haq, M.D., Ph.D.

Sarah J. Hill, M.D., Ph.D. (Pathology)

Shu-Ching Huang, Ph.D.

David Jackman, M.D.

Eric Jacobsen, M.D.

Caron Jacobson, M.D.

Rinath Jeselsohn, M.D.

Kenneth Kehl, M.D.

Kerry Kilbridge, M.D.

Mikyung Kim, Ph.D. (Dermatology)

Christopher Lathan, M.D.

Jacob Laubach, M.D.

Jose Leone, M.D.

R. Coleman Lindsley, M.D., Ph.D.

David Liu, M.D.

Joyce Liu, M.D.

Jens Lohr, M.D., Ph.D.

Julie-Aurore Losman, M.D., Ph.D.

Marlise Luskin, M.D.

Filipa Lynce, M.D.

J. Paul Marcoux II, M.D.

Catherine Marinac, Ph.D. Erica

Mayer, M.D. Nadine

McCleary, M.D. Otto

Metzger, M.D. Constantine

Mitsiades, M.D., Ph.D. Clifton

Mo, M.D. Mark Murakami,

M.D.

Lakshmi Nayak, M.B., B.S. (Neurology)

Sarah Nikiforow, M.D., Ph.D.

Oreofe Odejide, M.D.

Matthew Oser, M.D., Ph.D.

Heather Parsons, M.D.

Eirini Pectasides, M.D., Ph.D.

Kimberly Perez, M.D.

Mark Pomerantz, M.D.

Michael Rabin, M.D.

Osama Rahma, M.D.

Huma Rana, M.D.

Shoshana Rosenberg, Sc.D.

Douglas Rubinson, M.D., Ph.D.

Martin Sattler, Ph.D.

Ann Silk, M.D.

Elizabeth Stover, M.D., Ph.D.

Zuzana Tothova, M.D., Ph.D.

Hajime Uno, Ph.D.

Srinivas Viswanathan, M.D., Ph.D.

Martha Wadleigh, M.D.

Nikhil Wagle, M.D.

Eric S. Winer, M.D.

Matthew Yurgelun, M.D.

Baochun Zhang, B.Med., Ph.D.

## Assistant Professor, Part-time

David Dougherty, M.D.

Rochelle Scheib, M.D.

## Instructor

Aya Abu-El-Haija, M.B.B.S.

Utkarsh Acharya, D.O.

Saud Al Dubayan, M.B., B.S.

Nancy Andrea, M.D.

Elisa Aquilanti, M.D.

Ana Babic, Ph.D.

Sylvan Baca, M.D., Ph.D.

Veena Balakrishnan Iyer, M.B.B.S.

Jacob Berchuck, M.D. Amy

Bessnow, M.D. Patrick

Bhola, Ph.D. Giada

Bianchi, M.D.\* Leah

Biller, M.D. David Braun,

M.D., Ph.D. Kelly Burke,

M.D., Ph.D. Brittany

Bychkovsky, M.D. Edmond

Chan, M.D. Michael Cheng,

M.D.

Il-Kyu Choi, Ph.D.

Ugonma Chukwueke, M.D. (Neurology)

Diana Cirstea, M.D.

Ofir Cohen, Ph.D.

Steven Corsello, M.D.

Jennifer Crombie, M.D.

Felix Dietlein, M.D., Ph.D.

# Faculty Roster (continued)

Haitham Elmarakeby, Ph.D.

Temidayo Fadelu, M.D.

William Freed-Pastor, M.D., Ph.D.

Ana Garrido-Castro, M.D.

Christopher Gibson, M.D.

Shengqing Gu, Ph.D.

Annamaria Gulla, M.D.

Andrew Hantel, M.D.

Matthew Hemming, M.D., Ph.D.

Zachary Hunter, Ph.D.

Megan Insko, M.D., Ph.D.

Sheheryar Kabraji, M.B., Ch.B.

Austin Kim, M.D.

Erik Knelson, M.D., Ph.D.

Vidyasagar Koduri, M.D., Ph.D.

Carolyn Krasner, M.D.

Benjamin Lampson, M.D., Ph.D.

Elizabeth Lee, M.D.

Elizabeth Lightbody, Ph.D.

Jiye Liu, Ph.D.

Shengwu Liu, Ph.D.

Yang Liu, Ph.D.

Cédric Louvet, Ph.D.

Weidong Lu, Ph.D.

Jia Luo, M.D.

Kathleen Mahoney, M.D., Ph.D.

Robert Mallis, Ph.D.

Charlene Mantia, M.D.

Christopher Manz, M.D. Neil

McCarthy, Ph.D.

J. Ricardo McFaline-Figueroa, M.D., Ph.D. (Neurology)

Bradley McGregor, M.D.

Praveen Meka, M.D.

Priscilla Merriam, M.D.

Reid Merryman, M.D.

Brian Miller, M.D., Ph.D.

Peter Miller, M.D., Ph.D.

Jeffrey Morgan, M.D.

Omar Nadeem, M.D.

Prashant Nageshwar, M.D.

Abirami Natarajan, M.D.

Ajit Nirmal, Ph.D.

Samuel Ng, M.D., Ph.D.

Giacomo Oliveira, Ph.D.

Jay Oza, M.D., Ph.D.

Erin Parry, M.D., Ph.D. Ami

Patel, M.D. Anuj

Patel, M.D. Julia

Pimkina, M.D., Ph.D.

Philip Poorvu, M.D.

Rebecca Porter, M.D., Ph.D.

Rao Prabhala, Ph.D.\*

Srivatsan Raghavan, M.D., Ph.D.

Mahshid Rahmat, Ph.D.

Arvind Ravi, M.D., Ph.D.

Praful Ravi, M.D.

Julia Rotow, M.D.

Jacob Sands, M.D.

Benjamin Schlechter, M.D.

Kartik Sehgal, M.D.

Tal Sella, M.D.

Nilay Sethi, M.D., Ph.D.

Roman Shapiro, M.D.

Justin Simmons, M.D.

Harshabad Singh, M.B., B.S.

Romanos Sklavenitis-Pistofidis, M.D.

Sarah Slater, M.D.

Sandor Spisak, Ph.D.

Rajitha Sunkara, M.D.

Elisa ten Hacken, Ph.D.

Alok Tewari, M.D., Ph.D.

Matthew Vander Heiden, M.D., Ph.D.

Rahul Vedula, M.D.

Adrienne Waks, M.D.

Xiao X. Wei, M.D.

Wenxin Xu, M.D.

Shanye Yin, Ph.D.

Chen Yuan, Sc.D.

Yang Zeng, M.D., Ph.D.

Jin Zhou, M.D., Ph.D.

## Instructor, Part-time

Susan Schumer, M.D.

## Lecturer

Marilyn Hammer, Ph.D.

## Member of the Faculty (holding appointment)

Inhye Ahn, M.D.

Narjust Duma, M.D.

Leena Gandhi, M.D., Ph.D.

Antonio Giordano, M.D., Ph.D.

Shayna Sarosiek, M.D.

Eric L. Smith, M.D., Ph.D.

*\*Denotes secondary or tertiary hospital appointment in division*

# Selected Faculty Accomplishments

## Gregory Abel, M.D., M.P.H.

- Appointed, Faculty Member of Center for Bioethics, HMS

## Andrew Aguirre, M.D., Ph.D.

- Named a NextGen Star, American Association for Cancer Research

## Saud Al Dubayan, M.B., B.S.

- Recipient, Young Physician-Scientist Award, American Society for Clinical Investigation

## Kenneth Anderson, M.D.

- Recipient, State of Possible Award, Massachusetts Biotechnology Council

## Joseph Antin, M.D.

- Named Fellow, American Society for Transplantation and Cellular Therapy

## Philippe Armand, M.D., Ph.D.

- Recipient, Medical Oncology Team Science Award (PD-1 LyM.P.H.oma Team), DFCI

## Edward J. Benz, Jr., M.D.

- Recipient, 2020 Award for Leadership in Promoting Diversity, American Society of Hematology

## Himisha Beltran, M.D.

- Elected Member, American Society for Clinical Investigation

- Recipient, Inaugural Helen Trailblazer Award, Helen Gurley Brown Foundation

## Giada Bianchi, M.D.\*

- Recipient, Young Physician-Scientist Award, American Society for Clinical Investigation

## Myles Brown, M.D.

- Inducted, 2020 Class, National Academy of Medicine

## George Canellos, M.D.

- Recipient, 2020 Giants of Cancer Care Award: Lymphoma, OncLive

## James Cleary, M.D., Ph.D.

- Recipient, Ellen and Stephen Fine Award for Outstanding Teaching in Cancer Medicine, DFCI

## George Demetri, M.D.

- Elected Academy Fellow, American Association for Cancer Research

## Christina Dieli-Conwright, Ph.D.

- Recipient, Susan F. Smith Center for Women's Cancers Innovation Award, Breast and Gynecologic Cancer, DFCI

## David Dougherty, M.D., M.B.A.

- Recipient, Dana-Farber Cancer Care Collaborative Community Oncology Award, DFCI

## Benjamin Ebert, M.D., D.Phil.

- Recipient, 2021 Sjöberg Prize, Royal Swedish Academy of Sciences

- Recipient, 2021 Stanley J. Korsmeyer Award, American Society for Clinical Investigation

## Temidayo Fadelu, M.D.

- Awardee, 2021 Early Career Faculty Innovation Fund, Breast Cancer Research Foundation

## Gordon Freeman, Ph.D.

- Recipient, Medical Oncology Team Science Award (PD-1 LyM.P.H.oma Team), DFCI

## Matthew Freedman, M.D.

- Recipient, Medical Oncology Discovery Award, DFCI

## Irene Ghobrial, M.D.

- Appointed, Lavine Family Chair for Preventative Cancer Therapies, DFCI

## Selected Faculty Accomplishments (continued)

### Robert Haddad, M.D.

- Appointed, McGraw Chair in Head and Neck Oncology, DFCI

### William Hahn, M.D., Ph.D.

- Elected, National Academy of Medicine

### Glenn Hanna, M.D.

- Recipient, George P. Canellos, M.D. Award for Clinical Investigation and Care, DFCI

### Andrew Hantel, M.D.

- Appointed, Faculty Member of Center for Bioethics, HMS

### Rizwan Haq, M.D., Ph.D.

- Recipient, Wong Family Award, DFCI

### Sarah Hill, M.D., Ph.D.

- Recipient, Cancer Research Early Career Award, American Association for Cancer Research

- Recipient, Director's Early Independence Award, NIH

### William Kaelin, Jr., M.D.

- Recipient, Distinguished Scientist Award, Association of American Cancer Institutes

### Kenneth Kehl, M.D.

- Recipient, Clinical Scientist Development Award, Doris Duke Foundation

### Andrew Lane, M.D., Ph.D.

- Elected Member, American Society for Clinical Investigation

### R. Coleman Lindsley, M.D., Ph.D.

- Recipient, Nobility in Science Award, Myelodysplastic Syndromes Foundation

### David Liu, M.D.

- Recipient, Clinical Scientist Development Award, Doris Duke Foundation

### Joyce Liu, M.D.

- Recipient, George P. Canellos, M.D. Award for Clinical Investigation and Care, DFCI

### Marlise Luskin, M.D.

- Recipient, Lee M. Nadler, M.D. Extra Mile Award, DFCI

### J. Ricardo McFaline-Figueroa, M.D., Ph.D.

- Recipient, Harold Amos Medical Faculty Development Program Award, Robert Wood Johnson Foundation

### Bradley McGregor, M.D.

- Recipient, 2021 Dana-Farber Cancer Care Collaborative Research Award

### Priscilla Merriam, M.D.

- Recipient, Lee M. Nadler, M.D. Extra Mile Award, DFCI

### Matthew Meyerson, M.D., Ph.D.

- Elected Fellow, American Association for the Advancement of Science

- Recipient, 2020 Team Science Award (The Cancer Genome Atlas), American Association for Cancer Research

### Constantine Mitsiades, M.D., Ph.D.

- Elected Member, American Society for Clinical Investigation

### Lakshmi Nayak, M.B., B.S.

- Elected, Membership of the Faculty Council, HMS/HSDM

## Selected Faculty Accomplishments (continued)

### Kimmie Ng, M.D.

- Elected, 2022-2023 Scientific Program Chair, American Society of Clinical Oncology

### Samuel Ng, M.D., Ph.D.

- Recipient, Fellow to Faculty Scholar Award in Basic/Translational Research, American Society of Hematology

### Oreofe Odejide, M.D., M.P.H.

- Recipient, Junior Faculty Scholar Award, American Society of Hematology

### Praful Ravi, M.B., B.Chir., M.R.C.P.

- Recipient, 2021 Dana-Farber Cancer Care Collaborative Research Award

### Margaret Shipp, M.D.

- Recipient, Medical Oncology Team Science Award (PD-1 LyM.P.H.oma Team), DFCI

### Ramesh Shivdasani, M.D., Ph.D.

- Recipient, Medical Oncology Discovery Award, DFCI

### Robert Soiffer, M.D.

- Named Fellow, American Society for Transplantation and Cellular Therapy

### Eliezer Van Allen, M.D.

- Recipient, 2020 Team Science Award (The Cancer Genome Atlas), American Association for Cancer Research

### Srinivas Viswanathan, M.D., Ph.D.

- Recipient, George P. Canellos, M.D. Award for Clinical Investigation and Care, DFCI

### Martha Wadleigh, M.D.

- Recipient, Medical Oncology Prize for Innovation in Quality and Patient Safety, DFCI

### David Weinstock, M.D.

- Appointed, Lavine Family Chair for Preventative Cancer Therapies, DFCI

- Recipient, Postdoc and Graduate Student Mentor of the Year Award, DFCI

### Eric P. Winer, M.D.

- Elected, 2022-2023 President, American Society of Clinical Oncology

- Recipient, Ellen and Stephen Fine Award for Outstanding Teaching in Cancer Medicine, DFCI

### Alexi Wright, M.D.

- Recipient, Susan F. Smith Center for Women's Cancers Innovation Award, Breast and Gynecologic Cancer, DFCI

### Catherine Wu, M.D.

- Appointed, Lavine Family Chair for Preventative Cancer Therapies, DFCI